This may not be such a bad thing. As a company they will not be marketing just one treatment for MS as the ONLY treatment. When the drug reps talk to the docs they will give them pros/cons of each treatment and the docs will be able to see advantages for different patients. They will cross-market these drugs to obtain more market share so the docs will hear the message more than once. This is a case of Biogen not putting "all of their eggs in one basket", knowing that different treatments work for different patients. Therefore, more choices for patients. Just a thought!